- Paradigm shift in treatment utilises a patient’s B cells to produce antibodies against regulatory check-point targets
- Vaccine mimics check-point inhibitors – a multi billion-dollar drug class
- Broad platform patent filed to protect method of treatment
MELBOURNE Australia 12 February, 2018: Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, announces completion of early development of a new mimotope vaccine that will target and compete in the billion-dollar blockbuster anti-PD-1 immuno-oncology market. This announcement follows 18 months of intensive research conducted in partnership with the Medical University of Vienna.
A mimotope induces an antibody reaction against a target, in this case, a regulatory immune check-point known as PD-1. Mimotope induced antibodies may have advantages over synthetic antibodies including, safety, longer responses, memory and cost.
For further information please download PDF attached:
Download this document
